ArticleAlzheimer's & dementia (New York, N. Y.)2021
Antiviral treatment associated with reduced risk of clinical Alzheimer's disease-A nested case-control study.
Article in Alzheimer's & dementia (New York, N. Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Herpesviruses, antiviral treatment, and the risk of dementia - systematic review and meta-analysis.Alzheimer's research & therapy · 2025Pooled it
- Association between herpesviruses and alzheimer's disease: a meta-analysis based on case-control studies.Molecular and cellular biochemistry · 2025Pooled it
- Herpes Simplex Viral Infection Doubles the Risk of Dementia in a Contemporary Cohort of Older Adults: A Prospective Study.Journal of Alzheimer's disease : JAD · 2024Article
- Editorial: Cellular and molecular mechanisms of neurotropic viral infection.Frontiers in cellular neuroscience · 2024Article
- Viral pathogens increase risk of neurodegenerative disease.Nature reviews. Neurology · 2023Article
- Infectious origin of Alzheimer's disease: Amyloid beta as a component of brain antimicrobial immunity.PLoS pathogens · 2022Review
- PILRA polymorphism modifies the effect of APOE4 and GM17 on Alzheimer's disease risk.Scientific reports · 2022Article
- Does antiherpetic antiviral therapy reduce the risk of dementia?Nature reviews. Neurology · 2022Article
- Antiherpetic drugs: a potential way to prevent Alzheimer's disease?Alzheimer's research & therapy · 2022Article
- VALZ-Pilot: High-dose valacyclovir treatment in patients with early-stage Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Antiviral treatment associated with reduced risk of clinical Alzheimer's disease-A nested case-control study.Alzheimer's & dementia (New York, N. Y.) · 2021Article
- No association between antiviral treatment and risk of Alzheimer's disease in German outpatients.Alzheimer's & dementia (New York, N. Y.) · 2021Article
- The Hippocampal Vulnerability to Herpes Simplex Virus Type I Infection: Relevance to Alzheimer's Disease and Memory Impairment.Frontiers in cellular neuroscience · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn this nested case-control study, we investigated if antiviral treatment given prior to onset of Alzheimer's disease (AD) could influence incident AD.
methodsFrom a large population-based cohort study in northern Sweden, 262 individuals that later developed AD were compared to a non-AD matched control group with respect to prescriptions of herpes antiviral treatment. All included subjects were herpes simplex virus 1 (HSV1) carriers and the matching criteria were age, sex, apolipoprotein E genotype (ε4 allele carriership), and study sample start year.
resultsAmong those who developed AD, 6 prescriptions of antivirals were found, compared to 20 among matched controls. Adjusted for length of follow-up, a conditional logistic regression indicated a difference in the risk for AD development between groups (odds ratio for AD with an antiviral prescription 0.287, DISCUSSION: Antiviral treatment might possibly reduce the risk for later development of HSV1-associated AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.